Clinical Trials
18 trialsNCT06284122 2026-06-05
MorningLyte
The Lymphoma Academic Research Organisation
Phase 3 Recruiting
NCT06191744 2026-06-02
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT04224493 2026-06-01
SYMPHONY-1
Ipsen
Phase 3 Active not recruiting
NCT05100862 2026-05-27
MAHOGANY
BeOne Medicines
Phase 3 Recruiting
NCT06911502 2026-05-20
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene
Phase 3 Recruiting
NCT06149286 2026-05-06
OLYMPIA-5
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT04712097 2026-05-05
Celestimo
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT07562022 2026-05-01
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Sinocelltech Ltd.
Phase 3 Not yet recruiting
NCT05888493 2026-04-17
LEDA
Novartis
Phase 3 Active not recruiting
NCT06313996 2026-03-18
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
NCT07355283 2026-01-27
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 3 Not yet recruiting
NCT04680052 2025-12-22
InMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT02390869 2025-12-02
FIL_RENOIR12
Fondazione Italiana Linfomi - ETS
Phase 3 Active not recruiting
NCT05371093 2025-10-15
ZUMA-22
Gilead Sciences
Phase 3 Active not recruiting
NCT01650701 2025-09-25
RELEVANCE
The Lymphoma Academic Research Organisation
Phase 3 Completed
NCT05409066 2025-07-28
EPCORE FL-1
Genmab
Phase 3 Active not recruiting
NCT01996865 2025-07-10
MAGNIFY
Celgene
Phase 3 Completed
NCT01476787 2025-05-14
RELEVANCE
Celgene
Phase 3 Completed